Evidence map›Paper›PMID 39315250›Full record

ArticleResearch square2024

Ex Vivo Machine Perfusion as a Platform for Lentiviral Gene Delivery in Rat Livers.

Irina Filz von Reiterdank, Mohammadreza Mojoudi, Raphaela Bento, McLean Taggart, Antonia Dinicu, Gregory Wojtkiewicz, J H Coert, Aebele Mink van der Molen, Ralph Weissleder, Biju Parekkadan and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Irina Filz von ReiterdankMassachusetts General Hospital, Harvard Medical School.ORCID 0000-0002-0234-2704
Mohammadreza MojoudiMassachusetts General Hospital, Harvard Medical School.
Raphaela BentoMassachusetts General Hospital, Harvard Medical School.
McLean TaggartMassachusetts General Hospital, Harvard Medical School.
Antonia DinicuMassachusetts General Hospital, Harvard Medical School.
Gregory WojtkiewiczMassachusetts General Hospital, Harvard Medical School.
J H CoertUniversity Medical Center Utrecht.
Aebele Mink van der MolenUniversity Medical Center Utrecht.
Ralph WeisslederMassachusetts General Hospital.ORCID 0000-0003-0828-4143
Biju ParekkadanRutgers University.
Korkut UygunMassachusetts General Hospital, Harvard Medical School.

Funding

Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservationR01EB028782 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI Biju Parekkadan, Korkut Uygun · 2021 to 2026
$3.1M
NIBIB NIH HHS R01 EB028782
6 · The paper itself

Abstract

Developing new strategies for local monitoring and delivery of immunosuppression is critical to making allografts safer and more accessible. Ex vivo genetic modification of grafts using machine perfusion presents a promising approach to improve graft function and modulate immune responses while minimizing risks of off-target effects and systemic immunogenicity in vivo. This proof-of-concept study demonstrates the feasibility of using normothermic machine perfusion (NMP) to mimic in vitro conditions for effective gene delivery. In this study, lentiviral vectors carrying biosensor constructs with Gaussia Luciferase (GLuc) were introduced to rodent livers during a 72-hour perfusion period, with a targeted delivery of 3 × 10

Identifiers

PMID39315250
PMCPMC11419271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.